Unknown

Dataset Information

0

Pharmacological targeting of GLI1 inhibits proliferation, tumor emboli formation and in vivo tumor growth of inflammatory breast cancer cells.


ABSTRACT: Activation of the Hedgehog (Hh) pathway effector GLI1 is linked to tumorigenesis and invasiveness in a number of cancers, with targeting of GLI1 by small molecule antagonists shown to be effective. We profiled a collection of GLI antagonists possessing distinct mechanisms of action for efficacy in phenotypic models of inflammatory and non-inflammatory breast cancer (IBC and non-IBC) that we showed expressed varying levels of Hh pathway mediators. Compounds GANT61, HPI-1, and JK184 decreased cell proliferation, inhibited GLI1 mRNA expression and decreased the number of colonies formed in TN-IBC (SUM149) and TNBC (MDA-MB-231 and SUM159) cell lines. In addition, GANT61 and JK184 significantly down-regulated GLI1 targets that regulate cell cycle (cyclin D and E) and apoptosis (Bcl2). GANT61 reduced SUM149 spheroid growth and emboli formation, and in orthotopic SUM149 tumor models significantly decreased tumor growth. We successfully utilized phenotypic profiling to identify a subset of GLI1 antagonists that were prioritized for testing in in vivo models. Our results indicated that GLI1 activation in TN-IBC as in TNBC, plays a vital role in promoting cell proliferation, motility, tumor growth, and formation of tumor emboli.

SUBMITTER: Oladapo HO 

PROVIDER: S-EPMC5720365 | biostudies-literature | 2017 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

Pharmacological targeting of GLI1 inhibits proliferation, tumor emboli formation and in vivo tumor growth of inflammatory breast cancer cells.

Oladapo Helen O HO   Tarpley Michael M   Sauer Scott J SJ   Addo Kezia A KA   Ingram Shalonda M SM   Strepay Dillon D   Ehe Ben K BK   Chdid Lhoucine L   Trinkler Michael M   Roques Jose R JR   Darr David B DB   Fleming Jodie M JM   Devi Gayathri R GR   Williams Kevin P KP  

Cancer letters 20170928


Activation of the Hedgehog (Hh) pathway effector GLI1 is linked to tumorigenesis and invasiveness in a number of cancers, with targeting of GLI1 by small molecule antagonists shown to be effective. We profiled a collection of GLI antagonists possessing distinct mechanisms of action for efficacy in phenotypic models of inflammatory and non-inflammatory breast cancer (IBC and non-IBC) that we showed expressed varying levels of Hh pathway mediators. Compounds GANT61, HPI-1, and JK184 decreased cell  ...[more]

Similar Datasets

| S-EPMC6474814 | biostudies-literature
| S-EPMC5938062 | biostudies-literature
| S-EPMC2891639 | biostudies-literature
| S-EPMC4766375 | biostudies-literature
| S-EPMC10576977 | biostudies-literature
| S-EPMC5584896 | biostudies-literature
| S-EPMC5526044 | biostudies-other
| S-EPMC7835022 | biostudies-literature
2023-06-13 | GSE234267 | GEO
| S-EPMC3880137 | biostudies-literature